Search alternatives:
nm decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
m decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
12 m » 12 mm (Expand Search), 12 mg (Expand Search), 12 _ (Expand Search)
nm decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
m decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
12 m » 12 mm (Expand Search), 12 mg (Expand Search), 12 _ (Expand Search)
-
21
Vasopressin decreases EPSPs in CA2 after LTP induction.
Published 2013“…Bottom graph: typical example showing that the amplitude of the EPSP increased transiently (short-term facilitation) after HFS and then progressively to reach a plateau (long-term potentiation: LTP). Vasopressin (AVP 10 nM; 1 min) applied during LTP transiently decreased the EPSP amplitude. …”
-
22
-
23
-
24
Casein kinase 1.2 depletion decreases ZC3H11 phosphorylation.
Published 2016“…Procyclic cells expressing in situ tagged V5-CK1.2, with a tetracycline-inducible stem-loop RNAi construct, were induced with tetracycline (200g/ml). …”
-
25
-
26
-
27
Claudin V is decreased following infection with Mtb.
Published 2024“…Exposure to Mtb H37Rv and HN878 decreased claudin V expression compared to uninfected controls in the frontal cortex (E), cerebral nuclei (J), brain stem (O), thalamus (T), and hippocampus (Y). …”
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
(R)-albuterol decreases cytokine mRNA levels in activated T cells
Published 2011“…</p><p></p> (R)-albuterol, (S)-albuterol or racemic albuterol (R + S) at a dose (10M) were added to T (EL-4) cells pre-activated with mitogens Concanavalin A (Con A, 5 μg/ml) and phorbol myristate acetate (PMA, 100 ng/ml) (CP). …”
-
40
CDDO-Me radioprotection decreases with progressive oncogenic manipulations in HBECs and in a matched NSCLC line.
Published 2014“…Immortalized HBECs with (A) lenti-<i>KRas</i><sup>V12</sup>, (B) lenti-<i>KRas</i><sup>V12</sup> and sh<i>p53</i> knockdown, and (C) lenti-<i>KRas</i><sup>V12</sup>, sh<i>p53</i>, and <i>myc</i> overexpression. …”